Stock Price, News, Quote and Profile of REVVITY INC(NYSE:RVTY) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

REVVITY INC

NYSE:RVTY (5/17/2024, 7:24:34 PM)

After market: 110.23 0 (0%)

110.23

+1.77 (+1.63%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap13.62B

PE23.86

Fwd PE20.75

Dividend Yield0.27%

Analysts

IPO

Stock Screener Links

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm is focused on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and more. Its Life Sciences segment provides products and services targeted towards the life sciences market. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. Its portfolio includes research and development (R&D), clinical and diagnostics, platforms and automation, signals software, and advanced services and licensing. The company offers genomic analysis, protein analysis, cell analysis, and research solutions. The company offers clinical and diagnostics in the field of reproductive health, infectious diseases, autoimmunity, endocrinology, allergy, cancer, neurodegeneration, and rapid patient testing.